Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models
New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating ...
Why Is Silexion Therapeutics Stock Soaring Over 100% On Tuesday?
Silexion Therapeutics Corp. (NASDAQ:SLXN) released new preclinical data for SIL-204, its next-generation siRNA therapeutic ...
manilatimes8d
Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
Business Insider8d
Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds
Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi ...
Business Insider10d
Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models
Cayman Islands, January 28, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi ...
Business Wire9d
PESG Report: Silexion Therapeutics’ Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market
NEW YORK--(BUSINESS WIRE)--PESG Research releases new market update: Silexion Therapeutics (NASDAQ: SLXN)* continues to strengthen its position in the precision oncology landscape with ...
Benzinga.com9d
Why Is Silexion Therapeutics Stock Soaring Over 100% On Tuesday?
The findings contribute to validating systemic administration as an effective delivery approach, demonstrating significant tumor growth reduction in orthotopic pancreatic cancer models. While the ...
Nasdaq8d
Silexion Therapeutics Corp. Announces $3.3 Million Warrant Exercise and New Private Placement Financing
Silexion Therapeutics Corp. announced the immediate exercise of outstanding warrants to purchase 2,221,523 ordinary shares at an exercise price of $1.35 per share, expected to yield approximately ...